Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
801 On Other Exchanges
801 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

golden meditech holdings ltd (801) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GOLDEN MEDITECH HOLDINGS LTD (801)

Related News

No related news articles were found.

golden meditech holdings ltd (801) Related Businessweek News

No Related Businessweek News Found

golden meditech holdings ltd (801) Details

Golden Meditech Holdings Limited, an investment holding company, operates as an integrated healthcare enterprise in the People’s Republic of China. It operates through five segments: Medical Devices, Cord Blood Storage, Hospital Management, Medical Insurance Administration, and Chinese Herbal Medicines. The Medical Devices segment develops, manufactures, and sells medical devices and medical accessories. This segment also offers blood related medical devices, such as Autologous Blood Recovery System and its consumables. The Cord Blood Bank segment provides cord blood stem cell examination, processing, separation, storage, and other related services. The Hospital Management segment offers management services to hospitals. This segment also provides premium healthcare services; and operates a hospital, which specializes in hematology. The Medical Insurance Administration segment offers medical insurance administration services. This segment also provides claim processing and bill settlement services to medical insurance companies, hospitals, and policy holders. The Chinese Herbal Medicine segment is involved in the research, development, manufacture, and sale of Chinese herbal medicines. The company was formerly known as Golden Meditech Company Limited and changed its name to Golden Meditech Holdings Limited in March 2010. Golden Meditech Holdings Limited was incorporated in 2001 and is headquartered in Beijing, the People’s Republic of China.

1,661 Employees
Last Reported Date: 06/30/15
Founded in 2001

golden meditech holdings ltd (801) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, C...
Total Annual Compensation: $2.6M
Chief Operating Officer and Executive Directo...
Total Annual Compensation: $5.4M
Company Secretary, Executive Director and Mem...
Total Annual Compensation: $3.7M
Total Annual Compensation: $555.0K
Compensation as of Fiscal Year 2015.

golden meditech holdings ltd (801) Key Developments

Nanjing Xinjiekou Likely To Win Bid For China Cord Blood

PR Newswire August 27, 2015 Thursday 8:00 AM EST Nanjing Xinjiekou Sees High Chance of Winning Cord Blood Bidding War in China DATELINE: SHANGHAI, Aug. 27, 2015 The bidding war for China Cord Blood Corporation between two A-share-listed rivals is almost set to come to an end: it seems Nanjing Xinjiekou Department Store Co., Ltd ("Nanjing Xinjiekou", 600682.SH) is having increasing odds to win the bid on China Cord Blood Corporation ("CO", NYSE: CO) among a number of candidates. On August 26, five listed companies involved in the bid filed announcements respectively, together giving a clear picture of the takeover fight which is heading into the homestretch. Before this, two listed-companies, namely Nanjing Xinjiekou (600682.SH) and Zhongyuan Union Cell & Gene Engineering Corp., Ltd ("Zhongyuan", 600645.SH) both announced that they were in negotiations to acquire CO's assets or equity interest. While Nanjing Xinjiekou intended to take over CO's entire assets and all businesses in Mainland China, Zhongyuan only planned to acquire a minority equity interest of CO. CO, a U.S.-listed company that was incorporated in the Cayman Islands, primarily engage in the storage business of umbilical cord blood stem cells. It is the largest umbilical cord blood banking operator in China and the only cord blood banking operator with licenses in various Chinese cities including Beijing, Guangdong and Shandong. Nanjing Xinjiekou's announcement in line with message from CO's major shareholder On August 26, Nanjing Xinjiekou published an announcement which said that it was in talks with CO's major shareholder Golden Meditech (801.HK) about the acquisition of CO's assets and equity interests. On the same day, Golden Meditech published an announcement, saying that it "has the right" to make final decision in the deal. Apparently, this good news has fueled Nanjing Xinjiekou, the direct counterparty with Golden Meditech. According to Golden Meditech's announcement, its actual controller Mr. Kam had completed the purchase of CO's US$65,000,000 senior unsecured convertible notes from a KKR fund. The announcement also stated that Golden Meditech proposed an extraordinary general meeting to vote on Mr. Kam's proposal to transfer these convertible notes to Golden Meditech. On the same day, CO also published a filing to confirm the abovementioned convertible note transaction has been completed. Golden Meditech is the largest shareholder of CO, holding 38.31% of its outstanding shares. Assuming these convertible notes had been fully converted into ordinary shares, Golden Meditech and its actual controller Mr. Kam's position in CO would surge significantly to 51.7%. This number would further increase to 59.5% if shares from parties acting in concert with them, for example the management, were included in the calculation. According to the Cayman Islands' regulations, shareholders with more than 51% holdings in a company are entitled to dispose its assets. In other word, Golden Meditech and its actual controller have in fact already obtained the disposition right on CO's assets. On August 26, an announcement issued by Nanjing Xinjiekou said, "On August 11, the Company received the letter of response from the special committee of CO's board. In response to this, the Company has addressed every question and item it raised and engaged a financial advisor. The Company has communicated with the special committee on the acquisition issues, and has negotiated with CO's major shareholder Golden Meditech on the purchase matter after the special committee's introduction." In other words, Golden Meditech is deemed as the counterparty of Nanjing Xinjiekou. Previously, Nanjing Xinjiekou made an announcement to claim that it planned to take over all CO's assets and equity interests in relations with cord blood banking business in China, including all equity interests in related onshore companies, all assets CO required to operate cord blood banking business in China, and relevant business interests and business resources ("CO PRC Assets") for a consideration of at least RMB6 billion. This announcement indicated that the negotiation between the two parties had achieved genuine progress. Golden Meditech's attitude is particularly vital for Nanjing Xinjiekou to win the deal. As long as it gives the green light, Nanjing Xinjiekou will clear all legal impediments in the process of acquiring CO PRC Assets. An announcement published by Golden Meditech on May 8 said that it has entered into an agreement with Cordlife to acquire CO's US$25 million senior unsecured convertible notes as well as a 9.13% stake in CO. This transaction was subject to the approval from Cordlife's general meeting. If it was rejected, assuming all convertible notes had been converted into ordinary shares, Golden Meditech and its controlling shareholder's diluted interest in CO would remain over 51% and their deposition right on CO's assets would still be valid. The Singaporeans Says No to Zhongyuan Previously, Zhongyuan claimed that it would "combat against" Nanjing Xinjiekou's bid by offering high prices to acquire part of CO's stake from Singapore-listed Cordlife. Zhongyuan announced on August 6 that it intended to take over the equity interest and convertible notes of CO from Cordlife through a limited partnership named Jiaxing Huiling No.3 Investment. Zhongyuan did not given up. According to its announcement on August 25, a general meeting will be held on August 28 to vote on raising an overseas buyout fund. On August 26, a "regular" announcement was released by Zhongyuan, saying generally that all related works were still in progress. Being the key party in the takeover fight, the Singaporean company Cordlife had never confirmed its opinion, which raised a lot of speculations in the capital market. But on August 26, the Singaporean company issued an announcement in English which clearly clarified that the board of Cordlife strongly suggested that the shareholders should vote for the proposed transaction between the company and Golden Meditech other than that with Zhongyuan's. It said that the associated legal, transactional and reputation risks to accept the offer amendment would offset all the economic benefits. This suggests that Zhongyuan was unlikely to win the deal despite a better offer. A source close to the deal told China Business News that if Golden Meditech agrees to sell CO's China assets to Nanjing Xinjiekou, CO, whose major business is in China, will become a "shell company." In this case, there is no point for Zhongyuan or Golden Meditech to chase CO's shares and convertible bonds held by Cordlife. Commenting on Zhongyuan's general meeting on August 28, this person said there could be three possible intentions for Zhongyuan to set up an offshore M&A fund: Possible intention No. 1: Zhongyuan eyes on the cord blood banking business and assets. However, the abovementioned analysis indicated that to win the CO's Chinese business over Nanjing Xinjiekou is unlikely. Possible intention No. 2: Taking CO private through hostile acquisition. However, the circular issued by Cordlife on August 26 made it clear that it would ignore Zhongyuan's offer and urged its own shareholders to support the agreement it made with Golden Meditech previously. From here we could imply that Golden Meditech must be a very strong candidate to acquire CO's share and convertible bonds from C ordlife. Provided that Zhongyuan was able to collect the remaining 30% shares from the market, it would have no chance to privatize CO in which a hostile party owns 70% shares.

Golden Meditech Holdings Limited, Annual General Meeting, Jul 31, 2015

Golden Meditech Holdings Limited, Annual General Meeting, Jul 31, 2015., at 10:00 China Standard Time. Location: No. 4 Yong Chang North Road. Agenda: To consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors of the company and of the auditors for the year ended 31 March 2015; to declare a final dividend (with scrip option) for the year ended 31 March 2015; to re-elect directors; to authorise the board of Directors to fix the Directors' remuneration; to re-appoint the retiring auditors, KPMG, and to authorise the Board to fix their remuneration; and to consider increase in authorised share capital of the company.

Golden Meditech Holdings Limited Announces Financial Results for the Year Ended March 31, 2015

Golden Meditech Holdings Limited announced financial results for the year ended March 31, 2015. For the year, the company reported turnover of HKD 1,051,350,000 against HKD 1,085,068,000 a year ago. Loss after tax was HKD 881,437,000 against HKD 712,864,000 a year ago. Adjusted profit after tax was HKD 147,616,000 against HKD 141,133,000 a year ago. Loss attributable to equity shareholders was HKD 805,860,000 or 46.3 cents per basic and diluted share against HKD 429,081,000 or 33.6 cents per diluted share a year ago. Adjusted attributable to equity shareholders was HKD 29,885,000 or 1.7 cents per basic share against HKD 86,464,000 or 6.8 cents per basic share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
801:HK $1.04 HKD +0.04

801 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 801.
View Industry Companies

Industry Analysis


Industry Average

Valuation 801 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 0.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GOLDEN MEDITECH HOLDINGS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at